Literature DB >> 16499982

Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies.

Xavier Geets1, Jean-Francois Daisne, Milan Tomsej, Thierry Duprez, Max Lonneux, Vincent Grégoire.   

Abstract

BACKGROUND AND
PURPOSE: It has been shown that the use of pre-treatment FDG-PET impacted on the GTV delineation of pharyngo-laryngeal tumors. The goals of this study were to evaluate (1) the impact of FDG-PET GTV on dose distribution, and (2) the impact of per-treatment re-imaging on target volume delineation and dose distribution.
MATERIALS AND METHODS: Eighteen patients with squamous cell carcinoma of the oropharynx or larynx/hypopharynx were treated with curative intent by forward planning IMRT. Prior to treatment and on average after a dose of 46 Gy, all patients underwent contrast-enhanced CT, MRI and FDG-PET. After coregistration, GTVs were delineated manually on CT and MRI and automatically on FDG-PET. From these volumes, CTVs and PTVs were derived using consistent guidelines. Planning was performed using conformal radiotherapy.
RESULTS: GTVs, CTVs and PTVs based on pre-treatment FDG-PET were significantly smaller than those based on pre-treatment CT. Such difference in target volumes (TV) translated into a significant reduction in the irradiated volumes (reduction of 13 and 18% of the V50 and V95, respectively), Dmean to ipsilateral parotids (30.7 and 38.6% for FDG-PET and CT based plans, respectively) and to controlateral parotids (11.2 and 14.4% for FDG-PET and CT based plans, respectively). TVs based on per-treatment CT or MRI were also significantly smaller compared to those delineated from pre-treatment CT. Volumes delineated with MRI were significantly smaller than those delineated with CT. Due to radiotherapy-induced peri-tumoral inflammation, automatic delineation of FDG-PET GTV could not be performed. Such reductions in TVs translated into a reduction of the irradiated volumes compared to pre-treatment CT planning (reduction for V50 of 19 and 32%, and for V95 of 22 and 40%, for CT and MRI, respectively); Dmean to the ipsilateral parotids were also reduced (ipsilateral parotid Dmean of 20.4% for CT and of 20.1% for MRI compared to 24.7% for pre-treatment CT).
CONCLUSIONS: The use of pre-treatment FDG-PET and per-treatment CT or MRI significantly impacts on the delineation of TVs in pharyngo-laryngeal SCC, translating into more normal tissue sparing after conformal radiotherapy planning.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16499982     DOI: 10.1016/j.radonc.2006.01.006

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  26 in total

1.  Head and neck cancer: how imaging predicts treatment outcome.

Authors:  Robert Hermans
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

2.  A gradient-based method for segmenting FDG-PET images: methodology and validation.

Authors:  Xavier Geets; John A Lee; Anne Bol; Max Lonneux; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-13       Impact factor: 9.236

Review 3.  Balancing risk and reward in target delineation for highly conformal radiotherapy in head and neck cancer.

Authors:  Avraham Eisbruch; Vincent Gregoire
Journal:  Semin Radiat Oncol       Date:  2009-01       Impact factor: 5.934

4.  FDG-PET, a Complementary Modality to Computed-Tomography in Radiotherapy Target Volume Delineation for Head and Neck Cancer.

Authors:  Voichita Bar-Ad; Wenyin Shi; Madalina Tuluc; Nitin Ohri; David Cognetti; Joseph Curry; Charles Intenso
Journal:  J Nucl Med Radiat Ther       Date:  2012-02-01

Review 5.  Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.

Authors:  Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

Review 6.  Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive?

Authors:  Vincent Grégoire; Robert Jeraj; John Aldo Lee; Brian O'Sullivan
Journal:  Lancet Oncol       Date:  2012-06-28       Impact factor: 41.316

Review 7.  Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription.

Authors:  Søren M Bentzen; Vincent Gregoire
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

8.  A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data.

Authors:  Andrea Schaefer; Stephanie Kremp; Dirk Hellwig; Christian Rübe; Carl-Martin Kirsch; Ursula Nestle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-26       Impact factor: 9.236

9.  The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).

Authors:  Odré Palie; Pierre Michel; Jean-François Ménard; Caroline Rousseau; Emmanuel Rio; Boumédiene Bridji; Ahmed Benyoucef; Marc-Etienne Meyer; Khadija Jalali; Stéphane Bardet; Che Mabubu M'vondo; Pierre Olivier; Guillaume Faure; Emmanuel Itti; Christian Diana; Claire Houzard; Françoise Mornex; Frederic Di Fiore; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-29       Impact factor: 9.236

10.  Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target.

Authors:  Paolo Farace; Daniela D'Ambrosio; Flavia Merigo; Mirco Galiè; Cristina Nanni; Antonello Spinelli; Stefano Fanti; Anna Degrassi; Andrea Sbarbati; Domenico Rubello; Pasquina Marzola
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.